Form 10 Explorer
10-Q
Quarterly Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Jun 30, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
34 line items · 2 periods
XBRL
ItemJun 30, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
351,7092,958,659
Other Non-Operating Current Assets
197,97836,907
Total current assets
549,6872,995,566
Other Non-Current Assets
1,181,1390
Total assets
1,730,8262,995,566
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts Payable
5,893,0343,421,840
Other Current Liabilities
277,500277,500
Other Non-Operating Current Liabilities
70,0970
UIC License Agreement
70,097
Other Non-Operating Current Liabilities
6,932,3673,221,254
Short-Term Debt
6,900,0000
Total current liabilities
20,072,9986,920,594
Long term liabilities:
Other Non-Operating Non-Current Liabilities
1,260,903988,049
Other Non-Operating Current Liabilities
70,096130,041
UIC License Agreement
140,193130,041
Other Non-Operating Current Liabilities
404,991404,991
Total long-term liabilities
1,735,9901,523,081
Total liabilities
21,808,9888,443,675
Temporary Equity
94,178,40494,178,404
Stockholders’ deficit:
Total Stockholders' Equity
22
Total Stockholders' Equity
5,706,2315,468,006
Total Stockholders' Equity
(119,962,799)(105,094,521)
Total stockholders’ deficit
(114,256,566)(99,626,513)
Redeemable Convertible Preferred Stock
94,178,40494,178,404
Common Stock
22
Additional Paid-in Capital
5,706,2315,468,006
Retained Earnings
(119,962,799)(105,094,521)
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit
1,730,8262,995,566